
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
Coverage of the Academy of Managed Care Pharmacy Nexus 2021 Meeting, which took place in a hybrid format.






